(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 21.66% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 10.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 72.18%.
Penumbra's revenue in 2023 is $829,928,000.On average, 4 Wall Street analysts forecast PEN's revenue for 2023 to be $38,346,515,704, with the lowest PEN revenue forecast at $38,088,261,877, and the highest PEN revenue forecast at $38,472,224,552.
In 2024, PEN is forecast to generate $43,950,243,969 in revenue, with the lowest revenue forecast at $43,518,808,164 and the highest revenue forecast at $44,381,679,774.